SK1892004A3 - Substituted alkaminopyridazinone derivatives, process for the preparation thereof and pharmaceutical composition containing the same - Google Patents

Substituted alkaminopyridazinone derivatives, process for the preparation thereof and pharmaceutical composition containing the same Download PDF

Info

Publication number: SK1892004A3
Authority: SK; Slovakia
Prior art keywords: formula; acid addition; pharmaceutically acceptable; acceptable acid; hydrogen
Prior art date: 2001-09-27

Application number

SK1892004A

Other languages

English (en)

Slovak (sk)

Inventor

Jozsef Barkoczy

Gyula Simig

Nagy Peter Kotay

Gyorgy Levay

Istvan Gacsalyi

Marko Bernadett Martonne

Eva Schmidt

Andras Egyed

Hajnalka Kompagne

Csilla Leveleki

Kovacs Aniko Miklosne

Gabor Szenasi

Janos Wellmann

Laszlo Gabor Harsing

Original Assignee

Egyt Gyogyszervegyeszeti Gyar

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-09-27

Filing date

2002-09-26

Publication date

2004-10-05

2002-09-26 Application filed by Egyt Gyogyszervegyeszeti Gyar filed Critical Egyt Gyogyszervegyeszeti Gyar

2004-10-05 Publication of SK1892004A3 publication Critical patent/SK1892004A3/sk

Links

238000000034 method Methods 0.000 title claims description 16
239000008194 pharmaceutical composition Substances 0.000 title claims description 13
238000002360 preparation method Methods 0.000 title claims description 12
239000002253 acid Substances 0.000 claims abstract description 37
150000003839 salts Chemical class 0.000 claims abstract description 35
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 33
239000001257 hydrogen Substances 0.000 claims abstract description 29
125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 19
229910052736 halogen Chemical group 0.000 claims abstract description 17
150000002367 halogens Chemical group 0.000 claims abstract description 17
230000000949 anxiolytic effect Effects 0.000 claims abstract description 16
125000004432 carbon atom Chemical group C* 0.000 claims abstract description 15
125000000217 alkyl group Chemical group 0.000 claims abstract description 12
239000002249 anxiolytic agent Substances 0.000 claims abstract description 11
125000003545 alkoxy group Chemical group 0.000 claims abstract description 7
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 7
230000002708 enhancing effect Effects 0.000 claims abstract description 4
150000001875 compounds Chemical class 0.000 claims description 64
-1 Methoxytrifluoromethylphenyl Chemical group 0.000 claims description 13
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 12
239000004480 active ingredient Substances 0.000 claims description 8
125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 claims description 8
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
150000001412 amines Chemical class 0.000 claims description 4
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
238000005695 dehalogenation reaction Methods 0.000 claims description 3
125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 3
125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims description 2
MFXXTCPZOTXOOV-UHFFFAOYSA-N 4-[2-(4-pyridin-2-ylpiperazin-1-yl)ethylamino]-1h-pyridazin-6-one Chemical compound C1=NNC(=O)C=C1NCCN1CCN(C=2N=CC=CC=2)CC1 MFXXTCPZOTXOOV-UHFFFAOYSA-N 0.000 claims description 2
DXDDHJZKNLUJQT-UHFFFAOYSA-N 4-[2-(4-pyrimidin-2-ylpiperazin-1-yl)ethylamino]-1h-pyridazin-6-one Chemical compound C1=NNC(=O)C=C1NCCN1CCN(C=2N=CC=CN=2)CC1 DXDDHJZKNLUJQT-UHFFFAOYSA-N 0.000 claims description 2
NTTYWJGVUNURRC-UHFFFAOYSA-N 4-[2-[4-(4-fluorophenyl)piperazin-1-yl]ethylamino]-1h-pyridazin-6-one Chemical compound C1=CC(F)=CC=C1N1CCN(CCNC2=CC(=O)NN=C2)CC1 NTTYWJGVUNURRC-UHFFFAOYSA-N 0.000 claims description 2
230000003197 catalytic effect Effects 0.000 claims description 2
238000002156 mixing Methods 0.000 claims description 2
150000002431 hydrogen Chemical group 0.000 claims 3
239000003937 drug carrier Substances 0.000 claims 2
239000000546 pharmaceutical excipient Substances 0.000 claims 2
125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims 1
JCMVXCLLRPDLRG-UHFFFAOYSA-N 4-[2-(4-phenylpiperazin-1-yl)ethylamino]-1h-pyridazin-6-one Chemical compound C1=NNC(=O)C=C1NCCN1CCN(C=2C=CC=CC=2)CC1 JCMVXCLLRPDLRG-UHFFFAOYSA-N 0.000 claims 1
125000001309 chloro group Chemical group Cl* 0.000 claims 1
125000001153 fluoro group Chemical group F* 0.000 claims 1
238000004519 manufacturing process Methods 0.000 claims 1
230000019771 cognition Effects 0.000 abstract 1
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 45
238000012360 testing method Methods 0.000 description 25
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
241001465754 Metazoa Species 0.000 description 21
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 20
239000000203 mixture Substances 0.000 description 19
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical group [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 17
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
239000003054 catalyst Substances 0.000 description 13
230000000694 effects Effects 0.000 description 13
238000010992 reflux Methods 0.000 description 12
238000001816 cooling Methods 0.000 description 11
239000000706 filtrate Substances 0.000 description 11
229910052763 palladium Inorganic materials 0.000 description 10
229960003529 diazepam Drugs 0.000 description 9
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 9
239000011541 reaction mixture Substances 0.000 description 9
230000035939 shock Effects 0.000 description 9
241000700159 Rattus Species 0.000 description 8
239000013078 crystal Substances 0.000 description 8
239000000243 solution Substances 0.000 description 8
229910052799 carbon Inorganic materials 0.000 description 7
238000006243 chemical reaction Methods 0.000 description 7
239000000460 chlorine Substances 0.000 description 7
238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 6
238000005160 1H NMR spectroscopy Methods 0.000 description 6
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
238000004458 analytical method Methods 0.000 description 6
238000002474 experimental method Methods 0.000 description 6
239000005457 ice water Substances 0.000 description 6
239000000047 product Substances 0.000 description 6
230000001624 sedative effect Effects 0.000 description 6
NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 5
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 5
229910052801 chlorine Inorganic materials 0.000 description 5
YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
239000012153 distilled water Substances 0.000 description 5
IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 5
238000002844 melting Methods 0.000 description 5
230000008018 melting Effects 0.000 description 5
230000035515 penetration Effects 0.000 description 5
DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 5
OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 4
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
229920005372 Plexiglas® Polymers 0.000 description 4
230000036772 blood pressure Effects 0.000 description 4
QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 4
238000010438 heat treatment Methods 0.000 description 4
208000019901 Anxiety disease Diseases 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
241000700157 Rattus norvegicus Species 0.000 description 3
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
230000004872 arterial blood pressure Effects 0.000 description 3
229940049706 benzodiazepine Drugs 0.000 description 3
230000005587 bubbling Effects 0.000 description 3
229960002495 buspirone Drugs 0.000 description 3
201000010099 disease Diseases 0.000 description 3
230000014759 maintenance of location Effects 0.000 description 3
239000003921 oil Substances 0.000 description 3
NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
239000000932 sedative agent Substances 0.000 description 3
230000002269 spontaneous effect Effects 0.000 description 3
238000005303 weighing Methods 0.000 description 3
AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical class OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 description 2
125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 2
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
230000003276 anti-hypertensive effect Effects 0.000 description 2
230000036506 anxiety Effects 0.000 description 2
239000000010 aprotic solvent Substances 0.000 description 2
238000003556 assay Methods 0.000 description 2
239000012298 atmosphere Substances 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
150000001557 benzodiazepines Chemical class 0.000 description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
229910052794 bromium Inorganic materials 0.000 description 2
238000009903 catalytic hydrogenation reaction Methods 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
239000003651 drinking water Substances 0.000 description 2
235000020188 drinking water Nutrition 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
239000011737 fluorine Substances 0.000 description 2
229910052731 fluorine Inorganic materials 0.000 description 2
230000006870 function Effects 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
230000028252 learning or memory Effects 0.000 description 2
239000007788 liquid Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
230000037023 motor activity Effects 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
239000000902 placebo Substances 0.000 description 2
229940068196 placebo Drugs 0.000 description 2
239000003586 protic polar solvent Substances 0.000 description 2
239000002516 radical scavenger Substances 0.000 description 2
239000013558 reference substance Substances 0.000 description 2
239000007787 solid Substances 0.000 description 2
238000003756 stirring Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
VHFVKMTVMIZMIK-UHFFFAOYSA-N 1-(3-chlorophenyl)piperazine Chemical compound ClC1=CC=CC(N2CCNCC2)=C1 VHFVKMTVMIZMIK-UHFFFAOYSA-N 0.000 description 1
SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
QQCAYIPEZKIOBL-UHFFFAOYSA-N 4-(2-chloroethylamino)-1h-pyridazin-6-one;hydrochloride Chemical compound Cl.ClCCNC=1C=NNC(=O)C=1 QQCAYIPEZKIOBL-UHFFFAOYSA-N 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
AVVQYCNDMYIPGU-UHFFFAOYSA-N 4-[2-[4-(2-fluorophenyl)piperazin-1-yl]ethylamino]-1h-pyridazin-6-one Chemical compound FC1=CC=CC=C1N1CCN(CCNC2=CC(=O)NN=C2)CC1 AVVQYCNDMYIPGU-UHFFFAOYSA-N 0.000 description 1
TWMKPFQMPCZCRH-UHFFFAOYSA-N 4-[2-[4-(3-chlorophenyl)piperazin-1-yl]ethylamino]-1h-pyridazin-6-one Chemical compound ClC1=CC=CC(N2CCN(CCNC3=CC(=O)NN=C3)CC2)=C1 TWMKPFQMPCZCRH-UHFFFAOYSA-N 0.000 description 1
BTEIGBDNRMWUON-UHFFFAOYSA-N 5-chloro-4-[2-(4-pyrimidin-2-ylpiperazin-1-yl)ethylamino]-1h-pyridazin-6-one Chemical compound C1=NNC(=O)C(Cl)=C1NCCN1CCN(C=2N=CC=CN=2)CC1 BTEIGBDNRMWUON-UHFFFAOYSA-N 0.000 description 1
LZULALWFIKWMCH-UHFFFAOYSA-N 5-chloro-4-[2-[4-(2-fluorophenyl)piperazin-1-yl]ethylamino]-1h-pyridazin-6-one Chemical compound FC1=CC=CC=C1N1CCN(CCNC2=C(C(=O)NN=C2)Cl)CC1 LZULALWFIKWMCH-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
102000010029 Homer Scaffolding Proteins Human genes 0.000 description 1
208000023105 Huntington disease Diseases 0.000 description 1
208000006264 Korsakoff syndrome Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
208000036626 Mental retardation Diseases 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
239000007868 Raney catalyst Substances 0.000 description 1
NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
229910000564 Raney nickel Inorganic materials 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
201000008485 Wernicke-Korsakoff syndrome Diseases 0.000 description 1
206010048010 Withdrawal syndrome Diseases 0.000 description 1
210000003815 abdominal wall Anatomy 0.000 description 1
230000032683 aging Effects 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
125000005278 alkyl sulfonyloxy group Chemical group 0.000 description 1
229960004538 alprazolam Drugs 0.000 description 1
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
238000000540 analysis of variance Methods 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000002180 anti-stress Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
210000000702 aorta abdominal Anatomy 0.000 description 1
125000005279 aryl sulfonyloxy group Chemical group 0.000 description 1
239000002585 base Substances 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
229940092714 benzenesulfonic acid Drugs 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
230000004531 blood pressure lowering effect Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000001721 carbon Chemical group 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000003610 charcoal Substances 0.000 description 1
229960004782 chlordiazepoxide Drugs 0.000 description 1
ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 1
230000003920 cognitive function Effects 0.000 description 1
239000012050 conventional carrier Substances 0.000 description 1
239000012043 crude product Substances 0.000 description 1
238000007405 data analysis Methods 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
125000000532 dioxanyl group Chemical group 0.000 description 1
OHQLYLRYQSZVLV-UHFFFAOYSA-N dioxopalladium Chemical compound O=[Pd]=O OHQLYLRYQSZVLV-UHFFFAOYSA-N 0.000 description 1
230000035622 drinking Effects 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
239000003480 eluent Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000000556 factor analysis Methods 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000007941 film coated tablet Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
239000012458 free base Substances 0.000 description 1
238000003304 gavage Methods 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000001727 glucose Nutrition 0.000 description 1
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
229910000041 hydrogen chloride Inorganic materials 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
238000009434 installation Methods 0.000 description 1
239000011630 iodine Substances 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000008101 lactose Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000005259 measurement Methods 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
230000004899 motility Effects 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
229940105631 nembutal Drugs 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
231100000614 poison Toxicity 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
238000010149 post-hoc-test Methods 0.000 description 1
230000002980 postoperative effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
208000020016 psychiatric disease Diseases 0.000 description 1
238000011084 recovery Methods 0.000 description 1
238000000611 regression analysis Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000001593 sorbitan monooleate Substances 0.000 description 1
235000011069 sorbitan monooleate Nutrition 0.000 description 1
229940035049 sorbitan monooleate Drugs 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
238000013223 sprague-dawley female rat Methods 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000007858 starting material Substances 0.000 description 1
238000010972 statistical evaluation Methods 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
239000003440 toxic substance Substances 0.000 description 1
125000005208 trialkylammonium group Chemical group 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/22—Nitrogen and oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

SK1892004A 2001-09-27 2002-09-26 Substituted alkaminopyridazinone derivatives, process for the preparation thereof and pharmaceutical composition containing the same SK1892004A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
HU0103912A HU227237B1 (en)	2001-09-27	2001-09-27	Substituted alkylpyridazinone derivatives, process for their preparation, pharmaceutical compositions containing them
PCT/HU2002/000097 WO2003027078A1 (en)	2001-09-27	2002-09-26	Substituted alkylaminopyridazinone derivatives, process for the preparation thereof and pharmaceutical composition containing the same

Publications (1)

Publication Number	Publication Date
SK1892004A3 true SK1892004A3 (en)	2004-10-05

Family

ID=89979721

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SK1892004A SK1892004A3 (en)	2001-09-27	2002-09-26	Substituted alkaminopyridazinone derivatives, process for the preparation thereof and pharmaceutical composition containing the same
SK1902004A SK1902004A3 (en)	2001-09-27	2002-09-26	Substituted alkylaminopyridazinone derivatives, process for the preparation thereof and pharmaceutical composition containing the same

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SK1902004A SK1902004A3 (en)	2001-09-27	2002-09-26	Substituted alkylaminopyridazinone derivatives, process for the preparation thereof and pharmaceutical composition containing the same

Country Status (25)

Country	Link
US (2)	US20050043314A1 (pl)
EP (2)	EP1430034B1 (pl)
JP (2)	JP4472337B2 (pl)
KR (2)	KR100911069B1 (pl)
CN (3)	CN1325489C (pl)
AT (2)	ATE288910T1 (pl)
AU (2)	AU2002330656B9 (pl)
BR (2)	BR0212932A (pl)
CA (2)	CA2461467A1 (pl)
CZ (2)	CZ2004528A3 (pl)
DE (2)	DE60202969T2 (pl)
DK (2)	DK1430034T3 (pl)
EA (2)	EA006942B1 (pl)
ES (2)	ES2237696T3 (pl)
HU (1)	HU227237B1 (pl)
MA (2)	MA27137A1 (pl)
MX (2)	MXPA04002836A (pl)
NO (2)	NO326370B1 (pl)
NZ (2)	NZ532104A (pl)
PL (2)	PL369256A1 (pl)
PT (2)	PT1430047E (pl)
SI (2)	SI1430034T1 (pl)
SK (2)	SK1892004A3 (pl)
WO (2)	WO2003027078A1 (pl)
ZA (2)	ZA200402545B (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7504395B2 (en) *	2001-07-20	2009-03-17	Psychogenics, Inc.	Treatment for attention-deficit hyperactivity disorder
HU227592B1 (en) *	2002-11-13	2011-09-28	Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag	Use of substituted alkyl-piridazinone derivatives for the treatment of memory decline and learning malfunctions
JP5147866B2 (ja) *	2007-03-15	2013-02-20	メルク・シャープ・アンド・ドーム・コーポレーション	グルカン合成酵素阻害剤として有用であるピリダジノン誘導体
BR112020022006A2 (pt) *	2018-04-30	2021-01-26	Ribon Therapeutics Inc.	piridazinonas como inibidores de parp7
CN109053693B (zh)	2018-09-20	2021-02-05	顺毅股份有限公司	哒嗪胺类化合物的制备及其应用
WO2020223229A1 (en)	2019-04-29	2020-11-05	Ribon Therapeutics, Inc.	Solid forms of a parp7 inhibitor
TWI902715B (zh)	2019-10-30	2025-11-01	美商律幫治療股份有限公司	作為ｐａｒｐ７抑制劑的嗒酮
WO2022188889A1 (zh) *	2021-03-12	2022-09-15	杭州英创医药科技有限公司	作为parp7抑制剂的化合物
CN115490671B (zh) *	2022-10-21	2024-05-14	水木未来(北京)科技有限公司	Parp7抑制剂及其制备方法
CN118388414A (zh) *	2023-01-17	2024-07-26	中国药科大学	哒嗪酮类化合物及其制备方法、药物组合物和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH557820A (de) *	1970-11-12	1975-01-15	Sandoz Ag	Verfahren zur herstellung von neuen 2-(2-hydroxyalkyl)4,5-dihydro-pyridazin (2h)-3-onen.
IE62890B1 (en) *	1988-12-06	1995-03-08	Hafslund Nycomed Pharma	New piperazinylalkyl-3(2h)-pyridazinones process for the preparation thereof and the use thereof as agents lowering blood pressure
PL164079B1 (pl)	1990-06-15	1994-06-30	Akad Medyczna	posób wytwarzania nowych 2-amlnoalkilopochodnych 5-aminometyleno-6-/p-chlorofenylo /-4,5-dihydro-2H- plrydazyn -3-onu
HU209388B (en) *	1990-12-27	1994-05-30	Richter Gedeon Vegyeszet	Process for producing new 3/2h/-pyridazinones and pharmaceutical compositions comprising same
HU214320B (hu)	1991-12-20	1998-03-02	EGIS Gyógyszergyár Rt.	Eljárás új 3(2H)-piridazinon-származékok és ezeket tartalmazó gyógyszerkészítmények előállítására
HU224067B1 (hu)	1995-05-29	2005-05-30	Gyógyszerkutató Intézet Kft.	3(2H)-Piridazinon-származékok és e vegyületeket tartalmazó gyógyszerkészítmények
JP2004500314A (ja)	1998-06-05	2004-01-08	エギシュ　ヂョヂセルヂャール　エルテー	３（２ｈ）−ピリダジノン−４−置換アミノ−５−クロロ−誘導体の製法

2001
- 2001-09-27 HU HU0103912A patent/HU227237B1/hu not_active IP Right Cessation
2002
- 2002-09-26 EP EP02767729A patent/EP1430034B1/en not_active Expired - Lifetime
- 2002-09-26 WO PCT/HU2002/000097 patent/WO2003027078A1/en not_active Ceased
- 2002-09-26 US US10/490,959 patent/US20050043314A1/en not_active Abandoned
- 2002-09-26 BR BR0212932-9A patent/BR0212932A/pt not_active IP Right Cessation
- 2002-09-26 EA EA200400470A patent/EA006942B1/ru not_active IP Right Cessation
- 2002-09-26 DE DE60202969T patent/DE60202969T2/de not_active Expired - Lifetime
- 2002-09-26 EA EA200400469A patent/EA006392B1/ru not_active IP Right Cessation
- 2002-09-26 JP JP2003530685A patent/JP4472337B2/ja not_active Expired - Lifetime
- 2002-09-26 DE DE60202970T patent/DE60202970T2/de not_active Expired - Lifetime
- 2002-09-26 NZ NZ532104A patent/NZ532104A/en unknown
- 2002-09-26 AU AU2002330656A patent/AU2002330656B9/en not_active Ceased
- 2002-09-26 EP EP02762620A patent/EP1430047B1/en not_active Expired - Lifetime
- 2002-09-26 SK SK1892004A patent/SK1892004A3/sk unknown
- 2002-09-26 PL PL02369256A patent/PL369256A1/pl unknown
- 2002-09-26 CA CA002461467A patent/CA2461467A1/en not_active Abandoned
- 2002-09-26 CN CNB028204425A patent/CN1325489C/zh not_active Expired - Fee Related
- 2002-09-26 BR BR0212839-0A patent/BR0212839A/pt not_active IP Right Cessation
- 2002-09-26 US US10/491,151 patent/US6930110B2/en not_active Expired - Fee Related
- 2002-09-26 WO PCT/HU2002/000096 patent/WO2003027097A1/en not_active Ceased
- 2002-09-26 CN CNB028189752A patent/CN100368404C/zh not_active Expired - Fee Related
- 2002-09-26 PT PT02762620T patent/PT1430047E/pt unknown
- 2002-09-26 MX MXPA04002836A patent/MXPA04002836A/es active IP Right Grant
- 2002-09-26 SI SI200230107T patent/SI1430034T1/xx unknown
- 2002-09-26 JP JP2003530669A patent/JP2005508914A/ja active Pending
- 2002-09-26 MX MXPA04002838A patent/MXPA04002838A/es active IP Right Grant
- 2002-09-26 CZ CZ2004528A patent/CZ2004528A3/cs unknown
- 2002-09-26 PT PT02767729T patent/PT1430034E/pt unknown
- 2002-09-26 DK DK02767729T patent/DK1430034T3/da active
- 2002-09-26 AU AU2002328166A patent/AU2002328166B2/en not_active Ceased
- 2002-09-26 ES ES02767729T patent/ES2237696T3/es not_active Expired - Lifetime
- 2002-09-26 AT AT02762620T patent/ATE288910T1/de not_active IP Right Cessation
- 2002-09-26 CN CN200710104934XA patent/CN101099740B/zh not_active Expired - Fee Related
- 2002-09-26 CZ CZ2004532A patent/CZ2004532A3/cs unknown
- 2002-09-26 SK SK1902004A patent/SK1902004A3/sk unknown
- 2002-09-26 CA CA002461510A patent/CA2461510C/en not_active Expired - Fee Related
- 2002-09-26 NZ NZ532103A patent/NZ532103A/en unknown
- 2002-09-26 PL PL02369107A patent/PL369107A1/pl not_active IP Right Cessation
- 2002-09-26 ES ES02762620T patent/ES2237690T3/es not_active Expired - Lifetime
- 2002-09-26 DK DK02762620T patent/DK1430047T3/da active
- 2002-09-26 SI SI200230109T patent/SI1430047T1/xx unknown
- 2002-09-26 AT AT02767729T patent/ATE288899T1/de not_active IP Right Cessation
- 2002-09-26 KR KR1020047004607A patent/KR100911069B1/ko not_active Expired - Fee Related
- 2002-09-26 KR KR1020047004606A patent/KR100890667B1/ko not_active Expired - Fee Related
2004
- 2004-03-24 MA MA27588A patent/MA27137A1/fr unknown
- 2004-03-24 MA MA27589A patent/MA27068A1/fr unknown
- 2004-03-31 ZA ZA200402545A patent/ZA200402545B/en unknown
- 2004-03-31 ZA ZA200402544A patent/ZA200402544B/en unknown
- 2004-04-16 NO NO20041551A patent/NO326370B1/no not_active IP Right Cessation
- 2004-04-26 NO NO20041704A patent/NO325080B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
HU0103912D0 (en)	2001-12-28
JP2005508914A (ja)	2005-04-07
HU227237B1 (en)	2010-12-28
AU2002330656A2 (en)	2003-04-07
AU2002330656B2 (en)	2009-04-09
HK1069817A1 (en)	2005-06-03
PT1430034E (pt)	2005-06-30
BR0212839A (pt)	2004-10-13
KR100890667B1 (ko)	2009-03-26
NO20041704L (no)	2004-04-26
JP2005503437A (ja)	2005-02-03
AU2002328166A2 (en)	2003-04-07
CN1558904A (zh)	2004-12-29
ZA200402544B (en)	2005-04-26
SK1902004A3 (en)	2004-10-05
EP1430047A1 (en)	2004-06-23
NZ532104A (en)	2005-10-28
EP1430034A1 (en)	2004-06-23
ZA200402545B (en)	2005-04-26
CA2461510C (en)	2009-07-07
ATE288899T1 (de)	2005-02-15
CN1325489C (zh)	2007-07-11
CN101099740A (zh)	2008-01-09
EP1430047B1 (en)	2005-02-09
MA27068A1 (fr)	2004-12-20
US20040242873A1 (en)	2004-12-02
WO2003027097A1 (en)	2003-04-03
CA2461467A1 (en)	2003-04-03
SI1430034T1 (en)	2005-08-31
ATE288910T1 (de)	2005-02-15
DE60202969T2 (de)	2006-01-19
NZ532103A (en)	2005-08-26
WO2003027078A1 (en)	2003-04-03
SI1430047T1 (en)	2005-08-31
CZ2004528A3 (cs)	2004-08-18
ES2237690T3 (es)	2005-08-01
HK1115728A1 (en)	2008-12-05
PL369107A1 (pl)	2005-04-18
ES2237696T3 (es)	2005-08-01
BR0212932A (pt)	2004-10-13
EA200400469A1 (ru)	2004-08-26
NO326370B1 (no)	2008-11-17
JP4472337B2 (ja)	2010-06-02
US20050043314A1 (en)	2005-02-24
CN1571783A (zh)	2005-01-26
DK1430034T3 (da)	2005-05-30
DE60202970D1 (de)	2005-03-17
HUP0103912A3 (en)	2004-03-01
DE60202969D1 (de)	2005-03-17
KR100911069B1 (ko)	2009-08-06
NO20041551L (no)	2004-06-10
CN100368404C (zh)	2008-02-13
KR20040039446A (ko)	2004-05-10
US6930110B2 (en)	2005-08-16
HK1069816A1 (en)	2005-06-03
CZ2004532A3 (cs)	2004-08-18
CA2461510A1 (en)	2003-04-03
NO325080B1 (no)	2008-01-28
AU2002328166B2 (en)	2008-04-17
MA27137A1 (fr)	2005-01-03
MXPA04002836A (es)	2004-07-05
PL369256A1 (pl)	2005-04-18
DE60202970T2 (de)	2006-02-16
EA200400470A1 (ru)	2004-08-26
EA006392B1 (ru)	2005-12-29
MXPA04002838A (es)	2004-07-05
HUP0103912A2 (hu)	2003-07-28
EP1430034B1 (en)	2005-02-09
PT1430047E (pt)	2005-06-30
KR20040039445A (ko)	2004-05-10
DK1430047T3 (da)	2005-06-06
CN101099740B (zh)	2010-09-08
EA006942B1 (ru)	2006-06-30
AU2002330656B9 (en)	2009-09-03

Legal Events

Date	Code	Title	Description
2012-01-04	FB9A	Suspension of patent application procedure

Publication	Publication Date	Title
KR100911069B1 (ko)	2009-08-06	치환된 알킬아미노피리다지논 유도체, 이의 제조 방법 및이를 함유하는 약제학적 조성물
AU2002330656A1 (en)	2003-06-26	Substituted alkylaminopyridazinone derivatives, process for the preparation thereof and pharmaceutical composition containing the same
JP2005508914A5 (pl)	2005-12-22
HK1069816B (en)	2005-12-16	Substituted alkylaminopyridazinone derivatives, process for the preparation thereof and pharmaceutical composition containing the same
KR20040104608A (ko)	2004-12-10	피페리디닐-알킬아미노-피리다지논 유도체, 이의 제조방법, 및 이 화합물을 함유하는 약제 조성물
MXPA05005137A (es)	2005-07-22	Alquil-piridazinonas sustituidas para el tratamiento de trastornos de la memoria y del aprendizaje.
HK1115728B (en)	2011-04-29	Substituted alkylaminopyridazinone derivatives, process for the preparation thereof and pharmaceutical composition containing the same
HU227294B1 (en)	2011-02-28	Substituted alkylpyridazone derivatives, process for their preparation and pharmaceutical compositions containing them
HK1069817B (en)	2005-10-07	Substituted alkylaminopyridazinone derivatives, process for the preparation thereof and pharmaceutical composition containing the same